The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective
- PMID: 36130677
- PMCID: PMC9482796
- DOI: 10.1016/j.xphs.2022.09.014
The Race to Develop the Pfizer-BioNTech COVID-19 Vaccine: From the Pharmaceutical Scientists' Perspective
Abstract
At the outset of the coronavirus disease 2019 (COVID-19) pandemic, it was clear that a vaccine would be crucial for global health efforts. The Pfizer and BioNTech teams came together in a race against the virus, working to design, test, manufacture, and distribute a safe and efficacious vaccine in record time for people around the world. Here, we provide backstory commentary from the pharmaceutical scientist perspective on the challenges and solutions encountered in the development of the Pfizer-BioNTech mRNA COVID-19 vaccine (BNT162b2; b2; Comirnaty®; tozinameran). We discuss the foundational science that led to the decision to use an mRNA-based approach. We also describe key challenges in the identification of an optimal vaccine candidate and testing in clinical trials, the continuous efforts to improve the vaccine formulation in response to changing global health priorities and facilitate vaccine accessibility, and how vast quantities of vaccine doses were manufactured and safely delivered to every corner of the globe, all without compromising quality, science, and safety. The key to successfully delivering a safe and efficacious vaccine within nine months was a result of extraordinary, real-time, parallel effort and across-the-board collaboration between stakeholders on a global scale.
Keywords: Global Health; Lipid Nanoparticles; Vaccine; Vaccine delivery; mRNA.
Copyright © 2022 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Disclosures Authors are employees of Pfizer.
Figures
Similar articles
-
Abstracts of Presentations at the Association of Clinical Scientists 143rd Meeting Louisville, KY May 11-14,2022.Ann Clin Lab Sci. 2022 May;52(3):511-525. Ann Clin Lab Sci. 2022. PMID: 35777803 No abstract available.
-
Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.AAPS PharmSciTech. 2021 Jun 7;22(5):172. doi: 10.1208/s12249-021-02058-y. AAPS PharmSciTech. 2021. PMID: 34100150 Free PMC article. Review.
-
Use of Pfizer-BioNTech COVID-19 Vaccine in Persons Aged ≥16 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, September 2021.MMWR Morb Mortal Wkly Rep. 2021 Sep 24;70(38):1344-1348. doi: 10.15585/mmwr.mm7038e2. MMWR Morb Mortal Wkly Rep. 2021. PMID: 34555007 Free PMC article.
-
Public health impact of the Pfizer-BioNTech COVID-19 vaccine (BNT162b2) in the first year of rollout in the United States.J Med Econ. 2022 Jan-Dec;25(1):605-617. doi: 10.1080/13696998.2022.2071427. J Med Econ. 2022. PMID: 35574613
-
Interim Recommendations of the Advisory Committee on Immunization Practices for Use of Moderna and Pfizer-BioNTech COVID-19 Vaccines in Children Aged 6 Months-5 Years - United States, June 2022.MMWR Morb Mortal Wkly Rep. 2022 Jul 1;71(26):859-868. doi: 10.15585/mmwr.mm7126e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35771731
Cited by
-
The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.J Pharm Sci. 2023 Feb;112(2):386-403. doi: 10.1016/j.xphs.2022.11.001. Epub 2022 Nov 16. J Pharm Sci. 2023. PMID: 36351479 Free PMC article. Review.
References
-
- Bourla A. 1st ed. HarperCollins Publishers; 2022. Moonshot.
-
- World Health Organization . 2020. WHO Director-General's opening remarks at the media briefing on COVID-19.https://www.who.int/director-general/speeches/detail/who-director-genera... Available at.
-
- Pfizer . 2020. Pfizer Outlines Five-Point Plan to Battle COVID-19.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-ou... Available at.
-
- Pfizer . 2020. Pfizer and BioNTech to Co-Develop Potential COVID-19 Vaccine.https://www.pfizer.com/news/press-release/press-release-detail/pfizer-an... Available at.
-
- Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) 2022. COVID-19 Dashboard.https://www.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6 Accessed on Aug 1. Available at.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical